Two Very Different Paths to "Cannabis for Epilepsy"
Epilepsy is unique among the conditions discussed on this site because it is the one area where a cannabis-derived medicine has gone through the full FDA approval process, based on large randomized controlled trials — something that has not happened for whole-plant medical marijuana products sold through state dispensaries. Understanding the difference between the two is essential for patients and families researching options.
Epidiolex: The FDA-Approved Option
Epidiolex is a purified, plant-derived form of cannabidiol (CBD) approved by the FDA on June 25, 2018. It was the first — and remains the only — FDA-approved drug containing a cannabis-derived active ingredient. Epidiolex was initially approved for seizures associated with two rare and severe childhood-onset epilepsy syndromes, Lennox-Gastaut syndrome and Dravet syndrome. The FDA later expanded its approval to include seizures associated with tuberous sclerosis complex in patients one year of age and older.
- Epidiolex is manufactured under pharmaceutical quality standards, meaning its CBD content and purity are consistent from dose to dose, unlike many consumer CBD products.
- It does not contain meaningful amounts of THC and does not produce intoxication.
- Because of its FDA approval, the Drug Enforcement Administration placed Epidiolex in Schedule V, the least restrictive controlled substance category, and it was later removed from federal scheduling entirely, reflecting the strength of its clinical evidence and low abuse potential.
- Its approval was based on multiple randomized, double-blind, placebo-controlled clinical trials showing statistically significant reductions in seizure frequency for these specific syndromes.
State Medical Marijuana Programs: A Different Category
Separately from Epidiolex, epilepsy and seizure disorders are listed as qualifying conditions in most U.S. state medical marijuana programs, often specifically citing severe or treatment-resistant epilepsy. These programs allow access to a much broader range of cannabis products, including whole-plant flower, oils, and CBD/THC blends purchased through state-licensed dispensaries. This route is fundamentally different from an Epidiolex prescription in several important ways.
Why the Distinction Matters
- Regulatory oversight: Epidiolex is manufactured, tested, and dosed under FDA pharmaceutical standards. State dispensary products are regulated by state cannabis agencies, not the FDA, so potency and purity standards vary by state and by product.
- Evidence base: Epidiolex's approval rests on multiple large randomized controlled trials for specific epilepsy syndromes. Many artisanal or dispensary CBD and THC:CBD products used for epilepsy have not been tested in comparable trials, and effectiveness for seizure types outside of Dravet, Lennox-Gastaut, and tuberous sclerosis complex is less well established.
- THC content: Some state-program products contain THC, which carries its own risks, particularly in children, including potential effects on brain development and a different side-effect profile than pure CBD.
- Physician involvement: Epidiolex is prescribed and monitored by a neurologist as part of a standard medication regimen, including monitoring for interactions with other anti-seizure drugs (it is known to interact with clobazam, valproate, and other antiepileptic medications, sometimes raising liver enzyme levels). Dispensary access under state programs typically requires only a qualifying-condition certification, not the same level of ongoing specialist monitoring.
The Product Quality Problem
Product quality is a documented concern for consumer CBD products in particular. A widely cited study published in JAMA in 2017 tested CBD products purchased online and found that a substantial share were mislabeled: some contained significantly less CBD than the label claimed, some contained more, and a number contained detectable THC that was not disclosed on the label. Because CBD-only products are often marketed to parents seeking a non-intoxicating option for a child's seizures, mislabeling that results in unexpected THC exposure or inconsistent CBD dosing is a real safety concern that pharmaceutical-grade Epidiolex, with its FDA-mandated manufacturing and testing standards, is specifically designed to avoid.
What Patients and Families Should Weigh
For families dealing with treatment-resistant epilepsy, especially the specific syndromes Epidiolex is approved for, it is worth discussing the FDA-approved option directly with a neurologist before or alongside exploring state dispensary products, given its stronger evidence base and pharmaceutical-grade consistency. For seizure types or situations where Epidiolex is not indicated or has not helped, some patients and physicians do explore state-legal medical marijuana products, but this should be done with a treating neurologist's involvement given the risk of interactions with existing anti-seizure medications and the variability of unregulated product potency.
Medical Disclaimer
This article is for general educational purposes only and is not medical advice. It does not diagnose, treat, or cure epilepsy or any other condition, and it is not a substitute for care from a licensed neurologist or other qualified healthcare provider. Epidiolex is a prescription medication with known drug interactions and side effects; it and any other cannabis-derived product should only be used under the supervision of a physician familiar with a patient's full epilepsy treatment plan.